Themis Medicare Peer Comparison

NSE: THEMISMED | BSE: 530199

₹121.97

₹-0.63 (-0.51%)

As on 23-Sep-2026IST

Market cap

₹1,124 Cr

Revenue (TTM)

₹332 Cr

P/E Ratio

28.1

P/B Ratio

2.9

Div. Yield

0.4 %

Edit

	Themis Medicare	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	1,124	37,857	27,713	26,763	28,045
Revenue (₹ Cr)	332	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	23.20	414.00	288.22	387.35	-371.81
Net Margin (%)	6.81	11.23	14.79	26.01	-3.93
RoE (%)	-5.59	8.38	29.77	25.18	-3.85
Price to Earnings	28.11	92.56	96.15	69.30	--
Price-To-Book	2.90	7.52	20.65	15.51	3.50

Income Statement (₹ Cr)

	Themis Medicare	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	331.61	3,564.00	1,935.80	1,461.80	9,205.28
Total Income	340.79	3,686.00	1,948.58	1,489.25	9,449.59
Total Expenditure	373.56	2,792.00	1,485.56	919.25	8,195.15
EBITDA	-41.94	772.00	450.24	542.56	1,010.13
Depreciation	10.31	226.00	50.83	37.68	857.51
EBIT	-52.25	546.00	399.41	504.88	152.62
Interest	11.20	217.00	40.84	3.77	342.73
Other Income	9.18	122.00	12.78	27.45	244.31
Exceptional Items	92.09	12.00	0.00	0.00	-216.88
Profit before Tax	37.82	463.00	371.35	528.56	-162.68
Provision for Tax	14.62	49.00	83.14	141.21	209.13
Profit after Tax	23.20	414.00	288.22	387.35	-371.81

	Themis Medicare	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	398.58	4,940.00	1,288.82	1,653.56	8,162.62
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	33.17	1,712.00	202.03	42.40	5,044.14
Current Liabilities	166.16	1,622.00	835.87	230.82	4,758.28
Total Liabilities	597.90	8,100.00	1,451.43	1,549.26	15,513.53

	Themis Medicare	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	277.82	5,343.00	519.60	1,026.85	10,211.52
Current Assets	304.98	2,606.00	1,681.81	881.27	7,191.66
Total Assets	597.90	8,100.00	1,451.43	1,549.26	15,513.53
Total Debt*	82.99	1,859.00	393.17	8.18	4,720.27
Net Current Assets	138.82	984.00	845.94	650.46	2,433.38
Contingent Liabilities	25.85	770.26	12.25	15.38	99.76

	Themis Medicare	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	34.71	-22.00	159.18	118.34	892.30
Cash Flow from Investing Activities	-12.17	-783.00	-64.81	-223.94	-477.46
Cash from Financing Activities	-25.90	409.00	-39.81	261.12	-440.83
Net Cash Inflow / Outflow	-3.36	-396.00	54.56	155.52	-25.99

	Themis Medicare	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	10.37	4.07	26.97	20.14	6.61
ROE (%)	-5.59	8.38	29.77	25.18	-3.85
ROA (%)	3.91	4.94	24.77	21.93	-2.21
EBIT Margin (%)	-15.76	15.32	20.63	34.54	1.66
Net Margin (%)	6.81	11.23	14.79	26.01	-3.93
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Themis Medicare	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	-12.76	18.37	46.65	40.90	0.78
EBIT Growth (%)	-18,170.28	252.26	62.13	124.50	-70.53
Net Profit Growth (%)	361.15	377.85	89.49	104.15	-1,383.43
EPS Growth (%)	-139.76	1,001.33	78.60	42.32	-484.84
Book Value Growth (%)	6.60	29.77	42.49	94.96	2.28

	Themis Medicare	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	-51.63	95.00	94.68	69.29	-89.63
Price / Book Value	2.90	7.52	20.65	15.51	3.50
Dividend Yield (%)	0.41	0.00	0.09	0.08	0.00
EV/EBITDA	-28.46	50.93	61.36	48.96	31.86
Market Cap (₹ Cr)	1,349.79	23,064.69	0.00	19,988.69	29,731.27

	Themis Medicare	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.05	0.31	0.11	0.01	0.53
Short term debt to equity ratio	0.11	0.11	0.54	0.02	0.12
Current Ratio	1.84	1.61	2.01	3.82	1.51
Quick Ratio	1.35	1.06	1.14	2.82	0.87
Interest Coverage	4.38	3.13	10.09	141.16	0.53

	Themis Medicare	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	53.71	16.50	26.28	24.80	23.44
Asset Turnover	0.56	0.43	1.66	0.83	0.55
Receivable days	159.79	60.36	47.59	90.06	77.05
Inventory Days	69.71	64.42	62.58	61.02	77.13
Payable days	166.51	218.94	228.78	96.06	173.49
Cash Conversion Cycle	62.99	-94.15	-118.62	55.02	-19.30

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.